Binhui Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Binhui Huang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alan P. Venook
Helen Diller Family Comprehensive Cancer Center 1 San Francisco, California
19 shared publications - Amin Yaqubie
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
19 shared publications - Andrew B. Nixon
Department of Medicine, Duke University Medical Center, Durham, USA
19 shared publications - Anthony El-Khoueiry
USC Norris Comprehensive Cancer Center, Los Angeles, CA
19 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
19 shared publications - Federico Innocenti
University of North Carolina at Chapel Hill, Chapel Hill, NC
19 shared publications
Latest Publications
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Cox proportional hazards model results for PFS and OS. Each row reflects a model with that variable; models across all patients are stratified on treatment arm. Baseline HCV only includes those with pretreatment HCV titer data available (n = 43), and first sample HCV includes baseline HCV titer data for those with it available and cycle 2 data for those missing baseline (n = 53)
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Cox proportional hazards model results for PFS and OS. Each row reflects a model with that variable; models across all patients are stratified on treatment arm. Baseline HCV only includes those with pretreatment HCV titer data available (n = 43), and first sample HCV includes baseline HCV titer data for those with it available and cycle 2 data for those missing baseline (n = 53)
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 1. CONSORT diagram of those with evaluable sample for the HCV-based analyses for this manuscript
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 1. CONSORT diagram of those with evaluable sample for the HCV-based analyses for this manuscript
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 3. Kaplan-Meier curves for the progression-free survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 3. Kaplan-Meier curves for the progression-free survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 4. Kaplan-Meier curves for the overall survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 4. Kaplan-Meier curves for the overall survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 1. CONSORT diagram of those with evaluable sample for the HCV-based analyses for this manuscript
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 1. CONSORT diagram of those with evaluable sample for the HCV-based analyses for this manuscript
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 2. Tile plots of HCV viral ჼ00ter levels over ჼ00me for paჼ00ents treated with Doxorubicin and Sorafenib (A) or Sorafenib alone (B). For sample collected at the progression ჼ00me point, the ჼ00ming of progression is reflected as text in that ჼ00le.
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 2. Tile plots of HCV viral ჼ00ter levels over ჼ00me for paჼ00ents treated with Doxorubicin and Sorafenib (A) or Sorafenib alone (B). For sample collected at the progression ჼ00me point, the ჼ00ming of progression is reflected as text in that ჼ00le.
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Kaplan–Meier curves for the PFS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 3.51 for those with HCV-UN (vs. HCV-d), 95% CI: 1.58–7.78 (P = 0.002).
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Kaplan–Meier curves for the PFS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 3.51 for those with HCV-UN (vs. HCV-d), 95% CI: 1.58–7.78 (P = 0.002).
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Kaplan–Meier curves for the OS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 1.14 for those with HCV-UN (vs. HCV-d), 95% CI: 0.58–2.23 (P = 0.70).
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Kaplan–Meier curves for the OS distributions for patients who had detectable (HCV-d) versus undetectable (HCV-UN) HCV titer levels on their first evaluated sample. The HR based on a corresponding Cox proportional hazards model was 1.14 for those with HCV-UN (vs. HCV-d), 95% CI: 0.58–2.23 (P = 0.70).
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 4. Kaplan-Meier curves for the overall survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Supplementary Figure 4. Kaplan-Meier curves for the overall survival distributions for patients who have detectable (HCV-D) vs. undetectable (HCV-UN) HCV titer levels on their first evaluated sample, by treatment arm.
- Open Access
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
TABLE 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Patient characteristics by HCV titer status on first available sample, for patients with available sample
- 7 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Patient characteristics by HCV titer status on first available sample, for patients with available sample